Immunotherapy in Older Adults With Advanced Cancers: Implications for Clinical Decision-Making and Future Research

American Society of Clinical Oncology Educational Book
Ravindran KanesvaranRonald Maggiore

Abstract

Immunotherapy has expanded the therapeutic landscape for advanced cancers, including solid tumors and lymphomas. For many patients with cancer, these agents have been shown to have substantial efficacy and favorable toxicity compared with cytotoxic agents, particularly in the second-line setting. With the advent of anti-PD-1 and anti-PD-L1 checkpoint inhibitors, combination immunotherapy- and chemoimmunotherapy-based strategies have emerged as promising novel regimens to improve cancer-related outcomes. Older adults age 65 or older represent the growing majority of patients diagnosed with cancer. However, older adults are under-represented in clinical trials in general, as well as in the landmark studies that led to approval of these immunotherapy agents. Because of increasing age and attendant multimorbidity and impaired functional status, many of these patients seen in the community-based oncology practices would not have been considered eligible for such studies. Thus, the results of these studies are difficult to generalize to a broader patient population with these competing risks. Furthermore, robust evaluation of toxicities, effect on quality of life and functional status, and aging-related (i.e., immunosenescence) and i...Continue Reading

References

Dec 1, 1988·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·J M VoseJ Mailliard
Dec 30, 1999·The New England Journal of Medicine·L F HutchinsK S Albain
Apr 30, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Carol A TownsleyLillian L Siu
Jul 22, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hans von der MaaseMichael Arning
Mar 9, 2006·Nihon Ronen Igakkai zasshi. Japanese journal of geriatrics·Hajime Orimo
May 10, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Martine Extermann, Arti Hurria
Apr 1, 2014·Journal of the National Cancer Institute·Hanna K SanoffHyman B Muss
Jun 18, 2014·Current Opinion in Immunology·Tamas FulopAnis Larbi
Jul 30, 2014·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Hans WildiersArti Hurria
Dec 9, 2014·The New England Journal of Medicine·Stephen M AnsellPhilippe Armand
Jan 31, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·V A MorrisonS M Lichtman
Apr 4, 2015·Hematology/oncology Clinics of North America·Núria Malats, Francisco X Real
May 25, 2015·Current Oncology Reports·Clémentine SarkozyClaire Falandry
Jun 2, 2015·The New England Journal of Medicine·Julie BrahmerDavid R Spigel
Sep 29, 2015·The New England Journal of Medicine·Hossein BorghaeiJulie R Brahmer
Jan 26, 2016·The FEBS Journal·Gita ThanarajasingamStephen M Ansell
May 18, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Arti HurriaWilliam P Tew
Jun 9, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Alexander M LesokhinJohn Timmerman
Jun 30, 2016·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Philippe ArmandCraig H Moskowitz
Jul 13, 2016·The Oncologist·Jeffrey S WeberDirk Schadendorf
Oct 11, 2016·The New England Journal of Medicine·Martin ReckUNKNOWN KEYNOTE-024 Investigators
Oct 21, 2016·Journal of Translational Medicine·Sarah A WeissJudy Zhong
Oct 25, 2016·Journal of the American Geriatrics Society·Jennie JohnstoneMark Loeb
Feb 17, 2017·Therapeutic Advances in Hematology·Natalie GalaninaMichael R Bishop
Feb 18, 2017·The New England Journal of Medicine·Joaquim BellmuntUNKNOWN KEYNOTE-045 Investigators
Mar 9, 2017·Aging·Tomohiro F NishijimaHyman B Muss

❮ Previous
Next ❯

Citations

Apr 2, 2019·Clinical Nuclear Medicine·Francisco Javier García-GómezMaría de la Cinta Calvo-Morón
Oct 11, 2019·JAMA Otolaryngology-- Head & Neck Surgery·Zhen Gooi, Everett E Vokes
Mar 5, 2020·Expert Opinion on Drug Safety·José Mª Mazarico GallegoLuis Paz-Ares
Apr 15, 2020·Future Oncology·Vincenzo Di NunnoAlba A Brandes
Jul 8, 2020·Journal of the National Comprehensive Cancer Network : JNCCN·Sarguni SinghStacy Fischer
Apr 30, 2020·Lung Cancer Management·Chung-Shien LeeNagashree Seetharamu
May 9, 2019·Current Oncology Reports·Richard Curtis GodbyGrant R Williams
Aug 29, 2019·Expert Opinion on Pharmacotherapy·Jane E Rogers, Cathy Eng
Apr 14, 2021·Current Gastroenterology Reports·Brian T LeePriya Grewal
May 28, 2021·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Carolyn J PresleyMelisa L Wong
Jun 4, 2021·Frontiers in Immunology·Javier TrabaOlga M Anton
Aug 15, 2021·Journal for Immunotherapy of Cancer·Leisha A EmensJennifer K Litton
Aug 28, 2021·Current Oncology·Agnese PaderiLorenzo Antonuzzo
Oct 2, 2021·Current Treatment Options in Oncology·Arthur Winer, Efrat Dotan

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell Checkpoints & Regulators

Cell cycle checkpoints are a series of complex checkpoint mechanisms that detect DNA abnormalities and ensure that DNA replication and repair are complete before cell division. They are primarily regulated by cyclins, cyclin-dependent kinases, and the anaphase-promoting complex/cyclosome. Here is the latest research.

Related Papers

Annals of Oncology : Official Journal of the European Society for Medical Oncology
J NaidooJ D Wolchok
Human Vaccines & Immunotherapeutics
Neil J ShahAlexander Spira
Expert Review of Clinical Pharmacology
Giuseppe SantabarbaraCesare Gridelli
© 2022 Meta ULC. All rights reserved